Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours

Gut

Volumn 55, Issue 11, 2006, Pages 1586-1591

  Turner, G B ^a   Johnston, B T ^a   McCance, D R ^a   McGinty, A ^a   Watson, R G P ^a   Patterson, C C ^b   Ardill, J E S ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; NEUROKININ A; SOMATOSTATIN DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOID; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDGUT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; NEUROKININ A; PROGNOSIS; RETROSPECTIVE STUDIES; SOMATOSTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33750296895     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.092320     Document Type: Article

References (32)

1. Watson RG, Johnston CF, O'Hare MM, et al. The frequency of gastrointestinal endocrine tumours in a well-defined population-Northern Ireland 1970-1985. Q J Med 1989;72:647-57.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59.
3. Lauffer JM, Zhang T, Modlin IM. Review article: current status of gastrointestinal carcinoids. Aliment Pharmacol Ther 1999;13:271-87.
4. McStay MK, Caplin ME. Carcinoid tumour. Minerva Med 2002;93:389-401.
5. Greenberg RS, Baumgarten DA, Clark WS, et al. Prognostic factors for gastrointestinal and bronchopulmonary carcinoid rumors. Cancer 1987;60:2476-83.
6. McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994;81:1007-9.
7. Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229:815-21.
8. Agranovich AL, Anderson GH, Manji M, et al. Carcinoid tumour of the gastrointestinal tract: prognostic factors and disease outcome. J Surg Oncol 1991;47:45-52.
9. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998;43:422-7.
10. Rarstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:151-60.
11. Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-60.
12. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-90.
13. Schnirer II, Yao JC, Ajani JA. Carcinoid-a comprehensive review. Acta Oncol 2003;42:672-92.
14. De Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002;14:53-7.
15. Wangberg B, Nilsson O, Theodorsson E, et al. The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells. Br J Cancer 1991;64:23-8.
16. Schurmann G, Raeth U, Wiedenmann B, et al. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg 1992;16:697-701.
17. Shi W, Buchanan KD, Johnston CF, et al. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment. Clin Endocrinol (Oxf) 1998;48:303-9.
18. Imam H, Eriksson B, Lukinius A, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997;36:607-14.
19. Leong WL, Pasieka JL. Regression of metastotic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002;79:180-7.
20. Norheim I, Theodorsson-Norheim E, Brodin E, et al. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986;63:605-12.
21. Severini C, Improta G, Falconieri-Erspamer G, et al. The tochykinin peptide family. Pharmacol Rev 2002;54:285-322.
22. Bishop AE, Hamid QA, Adams C, et al. Expression of tachykinins by ileal and lung carcinoid tumors assessed by combined in situ hybridization, immunocytochemistry, and radioimmunoassay. Cancer 1989;63:1129-37.
23. Norheim I, Wilander E, Oberg K, et al. Tachykinin production by carcinoid tumours in culture. Eur J Cancer Clin Oncol 1987;23:689-95.
24. Conlon JM, Deacon CF, Richter G, et al. Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 1987;22:97-105.
25. Fenoglio-Preiser CM. Gastrointestinal neuroendocrine/neuroectodermal tumors. Am J Clin Pathol 2001;115(Suppl):S79-93.
26. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;i:238-9.
27. Moertal CG, Weiland LH, Nagorney DM, et al. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987;317:1699-701.
28. McGrath SJ, Johnston CF, O'Connor DT, et al. Pancreastatin-like immunoreactivity in human carcinoid disease. Regul Pept 1991;33:55-70.
29. Soreide JA, van Heerden JA, Thompson GB, et al. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg 2000;24:1431-6.
30. Burke AP, Thomas RM, Elsayed AM, et al. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997;79:1086-93.
31. Desai DC, O'Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept 1996;96:113-17.
32. Pirker RA, Pont J, Pohnl R, et al. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin Chem Lab Med 1998;36:837-40.